Isocitrate dehydrogenase mutations in gliomas

Neuro-Oncology

Volumn 18, Issue 1, 2016, Pages 16-26

  Waitkus, Matthew S ^a   Diplas, Bill H ^a   Yan, Hai ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

brain tumor metabolism; D 2 hydroxyglutarate; epigenetics; glioma genetics; isocitrate dehydrogenase mutations

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; ARGININE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ISOCITRIC ACID; TUMOR MARKER; ALPHA-HYDROXYGLUTARATE; ALPHA-KETOGLUTARIC ACID; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

AMINO ACID SUBSTITUTION; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; DECARBOXYLATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; EPIGENETICS; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; IDH1 GENE; IDH2 GENE; MALIGNANT TRANSFORMATION; NONHUMAN; OLIGODENDROGLIOMA; REVIEW; ANIMAL; BRAIN TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION;

ANIMALS; BRAIN NEOPLASMS; GLIOBLASTOMA; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; KETOGLUTARIC ACIDS; MUTATION;

EID: 84960440589     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov136     Document Type: Review

References (102)

1. Xu X, Zhao J, Xu Z, et al. Structures of human cytosolic NADP-Dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem. 2004; 279(32):33946-33957.
2. Hurley JH, Thorsness PE, Ramalingam V, et al. Structure of a bacterial enzyme regulated by phosphorylation, isocitrate dehydrogenase. Proc Natl Acad Sci USA. 1989;86(22): 8635-8639.
3. Macdonald MJ, Brown LJ, Longacre MJ, et al. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion. Biochim Biophys Acta. 2013; 1830(11):5104-5111.
4. Ronnebaum SM, Ilkayeva O, Burgess SC, et al. A pyruvate cycling pathway involving cytosolic NADP-Dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem. 2006;281(41):30593-30602.
5. Metallo CM, Gameiro Pa, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481(7381):380-384.
6. Filipp FV, Scott DA, Ronai ZA, et al. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res. 2012; 25(3):375-383.
7. Koh H-J, Lee S-M, Son B-G, et al. Cytosolic NADP+-Dependent isocitrate dehydrogenase plays a key role in lipid metabolism. J Biol Chem. 2004;279(38):39968-39974.
8. Bogdanovic E, Sadri A-R, Catapano M, et al. IDH1 regulates phospholipid metabolism in developing astrocytes. Neurosci Lett. 2014;582:87-92.
9. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-Associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225-234.
10. Comte B, Vincent G, Bouchard B, et al. Reverse flux through cardiac NADP(+)-isocitrate dehydrogenase under normoxia and ischemia. Am J Physiol Heart Circ Physiol. 2002;283(4): H1505-H1514.
11. Wise DR, Ward PS, Shay JES, et al. Hypoxia promotes isocitrate dehydrogenase-Dependent carboxylation of a-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA. 2011;108(49):19611-19616.
12. Hartong DT, Dange M, McGee TL, et al. Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle. Nat Genet. 2008;40(10):1230-1234.
13. Bleeker FE, Atai Na, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-Dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119(4): 487-494.
14. Winkler BS, DeSantis N, Solomon F. Multiple NADPH-producing pathways control glutathione (GSH) content in retina. Exp Eye Res. 1986;43(5):829-847.
15. Kim J, Kim KY, Jang H-S, et al. Role of cytosolic NADP+-Dependent isocitrate dehydrogenase in ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2009;296(3): F622-F633.
16. Lee SM, Koh H-J, Park D-C, et al. Cytosolic NADP(+)-Dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002;32(11):1185-1196.
17. Kil IS, Huh TL, Lee YS, et al. Regulation of replicative senescence by NADP+ -Dependent isocitrate dehydrogenase. Free Radic Biol Med. 2006;40(1):110-119.
18. Jo S-H, Lee S-H, Chun HS, et al. Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-Dependent isocitrate dehydrogenase. Biochem Biophys Res Commun. 2002; 292(2):542-549.
19. Kim SY, Park J-W. Cellular defense against singlet oxygen-induced oxidative damage by cytosolic NADP + -Dependent Isocitrate Dehydrogenase. Free Radic Res. 2003;37(3):309-316.
20. Kim J, Kim JI, Jang H-S, et al. Protective role of cytosolic NADP(+)-Dependent isocitrate dehydrogenase, IDH1, in ischemic pre-conditioned kidney in mice. Free Radic Res. 2011; 45(7):759-766.
21. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
22. Yan H, Parsons DWW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
23. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482-4490.
24. Balss J, Meyer J, MuellerW, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6): 597-602.
25. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30(1):7-11.
26. Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
27. Qi S-T, Yu L, Lu Y-T, et al. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep. 2011;26(6):1479-1485.
28. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341-347.
29. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149-1153.
30. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-6007.
31. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636-3643.
32. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72-79.
33. Lopez GY, Reitman ZJ, Solomon D, et al. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun. 2010;398(3):585-587.
34. Shibata T, Kokubu A, Miyamoto M, et al. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol. 2011;178(3):1395-1402.
35. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334-343.
36. Pansuriya TC, van Eijk R, d?Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43(12):1256-1261.
37. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43(12):1262-1265.
38. Wakimoto H, Tanaka S, Curry WT, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11): 2898-2909.
39. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102(13):932-941.
40. Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it?. Acta Neuropathol. 2013;125(5):621-636.
41. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3(7):730-741.
42. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-474.
43. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125(2):353-355.
44. Zhao S, Lin Y, Xu W, et al. Glioma-Derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261-265.
45. Dang L, White DW, Gross S, et al. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-744.
46. Jin G, Reitman ZJ, Spasojevic I, et al. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-Derived NADP-Dependent isocitrate dehydrogenase mutations. PLoS One. 2011;6(2):e16812.
47. XuW, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-Dependent dioxygenases. Cancer Cell. 2011;19(1):17-30.
48. Chowdhury R, Yeoh KK, Tian Y-M, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011;12(5):463-469.
49. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474-478.
50. Guan X, Vengoechea J, Zheng S, et al. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 2014;9(3):e91216.
51. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-483.
52. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472-479.
53. Sasaki M, Knobbe CB, Itsumi M, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012;26(18): 2038-2049.
54. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
55. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626-630.
56. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622-626.
57. Turcan S, Fabius AWM, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 2013;4(10): 1729-1736.
58. Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105(2):659-669.
59. Hirota K, Semenza GL. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun. 2005;338(1):610-616.
60. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-Enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483(7390):484-488.
61. Andronesi OC, Rapalino O, Gerstner E, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013;123(9): 3659-3663.
62. Reitman ZJ, Jin G, Karoly ED, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA. 2011;108(8): 3270-3275.
63. Izquierdo-Garcia JL, Viswanath P, Eriksson P, et al. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One. 2015; 10:e0118781.
64. Ohka F, Ito M, Ranjit M, et al. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour Biol. 2014;35(6):5911-5920.
65. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70(22):8981-8987.
66. Chen R, Nishimura MC, Kharbanda S, et al. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Natl Acad Sci USA. 2014;111(39):14217-14222.
67. Leonardi R, Subramanian C, Jackowski S, et al. Cancer-Associated isocitrate dehydrogenase mutations inactivate NADPHdependent reductive carboxylation. J Biol Chem. 2012;287(18): 14615-14620.
68. Reitman ZJ, Duncan CG, Poteet E, et al. Cancer-Associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem. 2014;289(34):23318-23328.
69. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014; 512(7514):324-327.
70. Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-Targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun. 2015; 3:1-12.
71. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79: 1381-1393.
72. Van Den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician?s perspective. Acta Neuropathol. 2010;120:297-304.
73. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764-772.
74. Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014;5(6):1515-1525.
75. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150-4154.
76. Jiao Y, Killela PJPJ, Reitman ZJZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709-722.
77. Juratli Ta, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012;110:325-333.
78. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560-1566.
79. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-1354.
80. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
81. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
82. Van Den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2013;19(19):5513-5522.
83. Wiestler B, Capper D, Sill M, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol. 2014;128(4):561-571.
84. Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;0:1-14.
85. Chung R, Whaley J, Kley N, et al. TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosom Cancer. 1991;3(I 991):323-331.
86. Rasheed BKA, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res. 1994;54:1324-1330.
87. Killela PJ, Pirozzi CJ, Reitman ZJ, et al. The genetic landscape of anaplastic astrocytoma. Oncotarget. 2013;5(6):1452-1457.
88. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110(15):6021-6026.
89. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-1479.
90. Labussiere M, Idbaih a, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23): 1886-1890.
91. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011; 333(6048):1453-1455.
92. Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol. 2012;123(6):853-860.
93. Kannan K, Inagaki A, Silber J, et al. Whole-Exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194-1203.
94. Huang D, Wang Z, He X-J, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51(8):969-976.
95. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-Term results of RTOG 9402. J Clin Oncol. 2013;31(3): 337-343.
96. Van Den Bent MJ, Brandes Aa, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-Term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-350.
97. Weller M, Weber RG, Willscher E, et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome -And transcriptome - wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015; 129(5):679-693.
98. Chan DT, Poon WS, Zhou L, et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol. 2014;28(2):177-186.
99. Labussiere M, Di Stefano AL, Gleize V, et al. TERT promoter mutations in gliomas, genetic associations and clinicopathological correlations. Br J Cancer. 2014;111(10):2024-2032.
100. Reitman ZJ, Choi BD, Spasojevic I, et al. Enzyme redesign guided by cancer-Derived IDH1 mutations. Nat Chem Biol. 2012;8(11): 887-889.
101. Losman J-A, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625.
102. Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation induced histone and DNA hypermethylation is progressively reversed by small molecule inhibition. Blood. 2014;125(2): 296-304.